Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares

Rhea-AI Filing Summary

Altimmune, Inc. Schedule 13G: Deep Track filing reports beneficial ownership disclosures for its affiliates and David Kroin. The filing states 19,417,221 shares (9.99%) reported for the named reporting person with shared voting and dispositive power as of April 30, 2026.

The disclosure uses a base of 194,366,579 shares (calculated from 194,199,358 shares outstanding as of April 24, 2026 plus 167,221 convertible shares). The filing also describes Pre-Funded Warrants (10,750,000) and Warrants (30,000,000) subject to a 9.99% Maximum Percentage exercise limitation that prevents exercises causing ownership to exceed 9.99%.

Key Figures

Reported beneficial ownership: 19,417,221 shares Percent of class: 9.99% Calculation base: 194,366,579 shares +3 more

6 metrics

Reported beneficial ownership 19,417,221 shares Amount reported for the named reporting person as of April 30, 2026

Percent of class 9.99% Percent of common stock corresponding to 19,417,221 shares

Calculation base 194,366,579 shares Calculated from 194,199,358 outstanding (Apr 24, 2026) plus 167,221 convertible shares

Pre-Funded Warrants 10,750,000 warrants Pre-Funded Warrants referenced in the beneficial ownership calculus

Warrants 30,000,000 warrants Warrants referenced and subject to 9.99% exercise cap

Shares outstanding (prospectus) 194,199,358 shares Shares outstanding as of April 24, 2026 per prospectus cited

Key Terms

Pre-Funded Warrants, Maximum Percentage, Beneficially owned, Shared dispositive power

4 terms

Pre-Funded Warrants financial

"The beneficially owned shares include 10,750,000 Pre-Funded Warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Maximum Percentage regulatory

"subject to a 9.99% Maximum Percentage exercise limitation"

Beneficially owned financial

"Amount beneficially owned: 19,417,221.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power regulatory

"Shared Dispositive Power 19,417,221.00"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Altimmune, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

02155H200

(CUSIP Number)

04/23/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 02155H200

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 19,417,221.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 19,417,221.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

19,417,221.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 02155H200

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 16,828,258.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 16,828,258.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,828,258.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.65 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 02155H200

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 19,417,221.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 19,417,221.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

19,417,221.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 02155H200

1

Names of Reporting Persons

Deep Track Special Opportunities Fund, LP.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,588,963.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,588,963.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,588,963.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.33 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Altimmune, Inc.
(b)	Address of issuer's principal executive offices: 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (iv) Deep Track Special Opportunities Fund, LP.
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (iv) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States (iv) Delaware
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP Number(s): 02155H200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 19,417,221.00
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 19,417,221.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 19,417,221.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	04/30/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	04/30/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	04/30/2026

Deep Track Special Opportunities Fund, LP.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP
Date:	04/30/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of April 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 194,366,579 shares, calculated using 194,199,358 Common Stock outstanding as of April 24, 2026, according to the Prospectus filed with the SEC on April 24, 2026 and 167,221 Common Stock that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 10,750,000 Pre-Funded Warrants exercisable to common stock and 30,000,000 Warrants, both, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants or Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. Deep Track Capital LP and David Kroin may be deemed to be considered beneficial owners of a combined 19,250,000 Common Stock, 10,750,000 Pre-Funded Warrants and 30,000,000 Warrants subject to the Maximum Percentage exercise limitation. Deep Track Biotechnology Master Fund Ltd. is the beneficial owner of 16,683,333 Common Stock, 9,316,667 Pre-Funded Warrants and 26,000,000 Warrants subject to the Maximum Percentage exercise limitation. Deep Track Special Opportunities Fund LP is the beneficial owner of 2,566,667 Common Stock, 1,433,333 Pre-Funded Warrants and 4,000,000 Warrants subject to the Maximum Percentage exercise limitation. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: April 30, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Special Opportunities Fund, LP. By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP

FAQ

What stake does Deep Track report in Altimmune (ALT)?

Deep Track reports 19,417,221 shares, equal to 9.99%. The figure reflects shared voting and dispositive power and is reported as of April 30, 2026 using a 194,366,579 share base from the issuer's April 24, 2026 prospectus.

How are the share totals in the ALT filing calculated?

The filing uses 194,366,579 shares as the calculation base. That number is derived from 194,199,358 shares outstanding as of April 24, 2026 plus 167,221 convertible shares referenced in the prospectus cited in the filing.

Do the reported holdings include warrants in the ALT Schedule 13G?

Yes — the disclosure includes Pre-Funded Warrants and Warrants. The filing lists 10,750,000 Pre-Funded Warrants and 30,000,000 Warrants referenced in the calculation, each subject to the 9.99% exercise limitation.

What is the 9.99% Maximum Percentage described in the ALT filing?

It is an exercise limitation. The issuer will not effect any exercise of Pre-Funded Warrants or Warrants if, after exercise, the holder would beneficially own more than 9.99% of outstanding common stock immediately after giving effect to the exercise.

Which entities and persons filed the Schedule 13G for ALT?

The filing is by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; Deep Track Special Opportunities Fund, LP; and David Kroin. Addresses and citizenships are listed for each filing person in Item 2 of the schedule.